Bioventures defy slowdown, launch IPOs in Korea in second half - KBR
| 068760 Stock | KRW 59,800 1,300 2.13% |
About 62% of Celltrion Pharm's investor base is looking to short. The analysis of current outlook of investing in Celltrion Pharm suggests that many traders are alarmed regarding Celltrion Pharm's prospects. The current market sentiment, together with Celltrion Pharm's historical and current headlines, can help investors time the market. In addition, many technical investors use Celltrion Pharm stock news signals to limit their universe of possible portfolio assets.
Celltrion |
Bioventures defy slowdown, launch IPOs in Korea in second half KBR
Read at news.google.com
 |
Celltrion Pharm Fundamental Analysis
We analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Celltrion Pharm is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Celltrion Pharm Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Celltrion Pharm stock to make a market-neutral strategy. Peer analysis of Celltrion Pharm could also be used in its relative valuation, which is a method of valuing Celltrion Pharm by comparing valuation metrics with similar companies.
Peers
Celltrion Pharm Related Equities
| 039840 | DIO | 0.55 |
| ||
| 086900 | Medy Tox | 0.72 |
| ||
| 041830 | InBody CoLtd | 2.29 |
| ||
| 036830 | Soulbrain Holdings | 5.00 |
|
Complementary Tools for Celltrion Stock analysis
When running Celltrion Pharm's price analysis, check to measure Celltrion Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celltrion Pharm is operating at the current time. Most of Celltrion Pharm's value examination focuses on studying past and present price action to predict the probability of Celltrion Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celltrion Pharm's price. Additionally, you may evaluate how the addition of Celltrion Pharm to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |